Resource Logo
AIDS Treatment Data Network

(ATDN) Two Studies for KS




 

Treatment Review #17 - March 1995

Tecogalen is an angiogenesis inhibitor. Angiogenesis is thought to be the process by which KS lesions grow. A drug than can inhibit, or stop this process may be able to control the KS. To participate in this trial, you must be HIV+ and have KS with 10 or more skin lesions. There is no T4 cell count requirement. You cannot have taken experimental treatments within 4 weeks of starting the study. You cannot have been on any anti-KS therapy for at least 3 weeks or have any opportunistic infection other than KS within 4 weeks prior to starting treatment. Another study is using IL-2. In a normal functioning immune system, IL-2 is a chemical that prompts special immune system cells to destroy diseased cells. IL-2 may help the immune system fight HIV and KS. An IL-2 study is being done at the National Institutes of Health in Bethesda, MD. The NIH will pay for airfare for every visit except the first. To participate in this study, you must be 18 years or older, male or female, HIV+, and have KS. Your T4 cell count must be over 200.



 


Copyright © 1995 -AIDS Treatment Data Network, Publisher. All rights reserved to AIDS Treatment Data Network. Reproduction of this article (other than one copy for personal reference) must be cleared through the AIDS Treatment Data Network. Email AIDS Treatment Data Network

Information in this article was accurate in March 1, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.